Interactive Case Challenge 2: Integrating Noninvasive Imaging in Crohn’s Disease Management
CE Information
0.5 contact hoursCompletion Time
30 minutesAvailable Until
March 19, 2026Posted By
NP EventsNavigate
Overview
Specialties
Acute Care, Adult, Family, Gerontological, and PediatricSubspecialties
Gastroenterology and HematologyClinical Topics
Crohn’s Disease, IBD, and Inflammatory Bowel DiseaseTarget Audience
The target audience for the education is gastroenterologists and gastroenterology nurse practitioners and physician associates who manage patients with CD.
Program Learning Goal
The goal of this activity is to improve knowledge, competence, and performance among GI HCP learners on treat-to-target strategies in CD, noninvasive imaging, and the newest treatment targets, including histological endpoints, to optimize and individualize patient care.
Learning Objectives
Upon completion of this activity, participants should be able to:
- 
Integrate noninvasive imaging-based assessments of mucosal and transmural inflammation into treatment response monitoring for patients with Crohn’s disease
 
Speakers
Chief, Pediatric Gastroenterology & Hepatology
Co-Director, Susan and Leonard Feinstein IBD Clinical Center
Mount Sinai Hospital
New York, New York
Dr. Dubinsky received her medical degree from Queen’s University, Canada. She completed her Pediatric Residency at Alberta Children’s Hospital, Calgary, Canada and her Clinical Fellowship in Gastroenterology and Nutrition at Sainte-Justine Hospital at the University of Montreal, Canada. She then completed her Research Fellowship in Inflammatory Bowel Disease at Cedars-Sinai Medical Center in Los Angeles where she then served as the Director of the Pediatric Inflammatory Bowel Disease Center before coming to Mount Sinai as the Chief of the Division of Pediatric Gastroenterology at the Mount Sinai Kravis Children's Hospital. She is also the Co-Director of the Susan and Leonard Feinstein Inflammatory Bowel Disease Clinical Center at Mount Sinai. Her primary research focuses on the influence of genetics and immune responses on the variability in clinical presentations, treatment responses and prognosis of early-onset IBD. Her other interests include the impact of IBD on fertility and pregnancy. She has lectured widely both nationally and internationally and has published in over 340 peer reviewed journals including The New England Journal of Medicine, Lancet, Gastroenterology, The Journal of Pediatric Gastroenterology and Nutrition, Inflammatory Bowel Diseases, Journal of Crohn’s and Colitis, and the American Journal of Gastroenterology. She also currently sits on the editorial boards of several leading journals. Mount Sinai Health System’s Marla C. Dubinsky, MD, and Laurie A. Keefer, PhD, are co-founders of Trellus Health, which has entered into an exclusive multi-year contract with Mount Sinai to commercialize a patent-pending GRITT-IBD™ resilience assessment and personalized integrated care pathways. Read about "The Science of Resilience Meets Technology" in the 2021 Mount Sinai Kravis Children's Hospital Pediatric Report. Dr. Dubinsky received the 2022 Sherman Prize National Recognizing for Excellence in Inflammatory Bowel Disease. Learn More Here. The state of Florida requires out-of-state professionals who are registered to provide telehealth services to display a hyperlink to the Florida Department of Health telehealth web page. This allows Florida patients who are receiving medical care by telehealth to confirm the provider’s licensure and Florida registration.
CE Information
This activity offers 0.5 contact hours to attendees.
Accredited by ANCC.
Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Disclosures
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:
Primary Author
Marla Dubinsky, MD
Professor of Pediatrics and Medicine
Chief, Division of Pediatric Gastroenterology and Nutrition
Co-Director, Susan and Leonard Feinstein IBD Clinical Center
Mount Sinai Kravis Children’s Hospital
Ichan School of Medicine, Mount Sinai New York
New York, New York
Marla Dubinsky, MD: consultant/advisor/speaker: AbbVie, Abivax, AstraZeneca, Bristol Myers Squibb, Celltrion, Janssen, Lilly, Merck, Pfizer, Prometheus Labs, Takeda.
The planners and content peer reviewers from Clinical Care Options, LLC, Practicing Clinicians Exchange, and the American Gastroenterological Association do not have any relevant financial relationships to disclose, except Kimberly Orleck, PA-C, and Amy Stewart, MSN, FNP-C as noted below:
Kimberly Orleck, PA-C: consultant/advisor/speaker: AbbVie, Ardelyx, Janssen, Pfizer, Salix, Takeda.
Amy Stewart, MSN, FNP-C: consultant/advisor/speaker: Bristol Myers Squibb, Celltrion, Exact Sciences, Ferring, Johnson & Johnson, Lilly, Pfizer, Phathom, Prometheus, Sanofi Regeneron, Takeda
Register For This Activity
OnDemand Activity Registration
Select this option to access the activity at no cost